Trump 100% Tariff on Indian Pharma: A Major Blow to Exports
US President Donald Trump has announced a sweeping trade move, imposing Trump 100% tariff on Indian pharma exports of branded and patented drugs from October 1, 2025. The policy will apply unless companies set up pharmaceutical manufacturing plants in America. The decision is expected to shake India’s $8.7 billion drug trade with the US, making it a critical issue for Indian exporters and global healthcare.
India’s Pharma Exports at Risk
The US is India’s largest export market for medicines. According to the Pharmaceuticals Export Promotion Council of India, 31% of India’s total pharma exports in FY24 went to the US. In just the first half of 2025, India exported $3.7 billion worth of pharmaceutical products to America. With the Trump 100% tariff on Indian pharma, the trade balance could be severely disrupted.
Impact on US Consumers
India supplies 45% of generics and 15% of biosimilars used in America. If the tariffs extend beyond branded drugs, it could trigger higher prices, shortages, and inflation in the US healthcare system. Since Indian firms operate on thin margins, they may pass on increased costs to US consumers and insurers, making the Trump 100% tariff on Indian pharma a concern for American patients too.
Broader Tariff Wave
Trump’s new tariff package also includes 50% duty on kitchen cabinets, 30% on upholstered furniture, and 25% on heavy trucks. Justifying the move, Trump claimed the taxes are needed “for national security and other reasons,” signaling that the trade war logic is expanding beyond traditional industries.
FAQs on Trump 100% Tariff on Indian Pharma
Q1: What is the Trump 100% tariff on Indian pharma?
A: It is a new trade policy imposing 100% tariffs on branded and patented drug imports from India starting October 1, 2025.
Q2: How will Trump 100% tariff on Indian pharma affect Indian companies?
A: Companies like Dr Reddy’s, Sun Pharma, and Zydus may face revenue losses and higher operating costs.
Q3: Will US consumers pay more due to Trump 100% tariff on Indian pharma?
A: Yes, higher tariffs could lead to drug shortages, price hikes, and inflation in the American healthcare system.
